ClinicalTrials.gg
Not yet recruitingNCT07946250Updated Nov 18, 2026

A Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin

An interventional study of Broc Shot Capsules Intervention and Placebo Intervention in Reactive Skin, Blemish-Prone Skin and Hormonally Affected Skin, sponsored by BrocShot Inc. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by BrocShot Inc · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Planned enrollment
214th of 354
50 · median 78
Started
2026
with 7 others
No phase
78 of 374
9 open now
Primary completion
2027-01
later than 15 of 28 live
Registered
374th of 374
by date

Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 214th largest by planned enrollment of the 354 interventional ones that give a count, is one of 8 that started in 2026, is one of 78 with no phase, reaches primary completion later than 15 of the 28 other live ones, and was the 374th registered.

Acne Vulgaris

792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger; 20 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, fully decentralized (remote) clinical trial evaluating the effects of Broc Shot Capsules on skin appearance and comfort in adults with reactive, blemish-prone, or hormonally affected skin. Fifty participants aged 18-65 years will be randomly assigned in a 1:1 ratio to receive either Broc Shot Capsules (active) or matched placebo capsules for 8 weeks.

Participants will take 2 capsules once daily and complete self-reported questionnaires and standardized self-captured skin photographs at Baseline, Week 4, and Week 8 via a secure online study platform. Expert dermatologist grading of photographs will be conducted remotely at each timepoint. The study is designed to substantiate consumer product claims related to visible skin improvement and participant-reported skin comfort, and is not intended to evaluate treatment of any clinical dermatological disease.

03

Conditions studied

  • Reactive Skin
  • Blemish-Prone Skin
  • Hormonally Affected Skin
  • Acne
  • Rosacea
  • Eczema
  • Psoriasis
  • Skin Irritation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years (inclusive) at the time of consent.
  • Self-reported skin concerns matching at least one of the following descriptions: I have red, itchy skin patches
  • I have dry, flaky/scaley skin patches
  • my skin has blemishes such as pimples, discoloured papules (small, tender bumps that are pink/red/purple/or darker than your natural skin tone) or pustules (a distinct white or yellow pus-filled center surrounded by a red base).
  • Generally healthy adults who are willing and able to follow the study protocol for the full 8-week duration, including taking 2 capsules of the study product once daily for 8 consecutive weeks without skipping days, answering questionnaires at Baseline, Week 4, and Week 8, and following the photograph submission protocol at Baseline, Week 4, and Week 8.
  • Willing to avoid initiating any new topical or oral skincare products, prescription medications targeting skin, or other dietary supplements specifically marketed for skin benefit during the study period.
  • Participants currently using such products who have been using them consistently for at least 3 months prior to enrollment and are willing to continue unchanged throughout the study are eligible.
  • Willing to maintain their current diet, lifestyle, sleep pattern, sun exposure habits, and skincare routine for the duration of the trial.
  • Resides within the United States.
  • Access to a smartphone or computer with internet connection and the ability to use the Citruslabs digital study platform.

Exclusion criteria

Exclusion Criteria:

  • Known allergy, , or intolerance to broccoli, horseradish, other cruciferous vegetables (Brassicaceae family), or any component of the study product or placebo capsule.
  • Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Currently taking prescription anticoagulant medications (e.g., warfarin, apixaban, rivaroxaban) due to the potential for product ingredients to interact with anticoagulant activity.
  • History of a severe or unstable medical condition that, in the opinion of the study team, would prevent safe participation or adherence to the protocol, including active cancer treatment.
  • Currently using any oral, topical, or biologic prescription medication specifically indicated for a diagnosed dermatological condition, unless the regimen has been stable for at least 3 months and no changes are planned during the study period.
  • Planned dermatological procedures during the study period (e.g., chemical peels, laser treatments, microneedling, injectable cosmetic procedures) that could confound skin appearance assessments.
  • Currently enrolled in another clinical or consumer research study, or plans to enroll in any such study during the 8-week study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    BrocShot Collagen

    Dietary Supplement: Broc Shot Capsules Intervention

  • Placebo comparator
    Placebo Comparator

    Dietary Supplement: Placebo Intervention

Interventions

  • Dietary supplementBroc Shot Capsules Intervention

    Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

  • Dietary supplementPlacebo Intervention

    Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

06

What researchers measure

Primary outcomes

  1. Clinician-Assessed Change in Overall Skin Appearance

    Change from Baseline in overall skin appearance graded by a qualified dermatologist reviewing participant-submitted digital photographs using a binary Yes/No improvement scale assessing overall skin health, pigmentation, dryness, brightness, scarring, blemishes, redness, and flaking

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Participant-Reported Change in Skin Appearance

    Change from Baseline in self-reported skin appearance assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  2. Participant-Reported Change in Skin Clarity

    Change from Baseline in self-reported skin clarity assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  3. Participant-Reported Change in Skin Calmness

    Change from Baseline in self-reported skin calmness assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  4. Participant-Reported Change in Visible Skin Concerns

    Change from Baseline in self-reported visible skin concerns assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  5. Participant-Reported Change in Skin Texture

    Change from Baseline in self-reported skin texture assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  6. Participant-Reported Change in Skin Luminosity

    Change from Baseline in self-reported skin luminosity assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  7. Participant-Reported Change in Skin Age Appearance

    Change from Baseline in self-reported skin age appearance assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  8. Participant-Reported Change in Itching and Irritation

    Change from Baseline in self-reported itching and irritation assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  9. Participant-Reported Change in Skin Comfort

    Change from Baseline in self-reported skin comfort assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

  10. Participant-Reported Change in Skin Confidence

    Change from Baseline in self-reported skin confidence assessed via a participant-reported skin questionnaire

    Time frame: Baseline, Week 4, and Week 8

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 62 industry-sponsored interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's planned 2 months is below that.

Counting every sponsor, half of 120 studies reached it within 9 months; a quarter within 4 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946250
Lead sponsor
BrocShot Inc
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Gracia Walker
Contact
gracia@brocshot.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion